Asper Biotech | GenomeWeb

Asper Biotech

Premium
Asper Biotech launched two arrays this month. The first is a chip for screening six genes connected with hereditary breast and ovarian cancer.
 
The company said the array enables users to analyze 88 mutations in the BRCA1, BRCA2, CHEK2, RAD51, NBN, and CASP8 genes.
 

Asper also launched an array for Wilson disease screening that assays 104 mutations in the ATP7B gene. The Wilson disease chip was developed and validated with the University of Brno in the Czech Republic, Asper said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.